Publications
- Infliximab Biosimilar (Remsima (TM)) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre2017 | First Faculty of Medicine
- Guidelines for the administration of biological therapy in patients with inflammatory bowel diseases: third, updated edition2016 | First Faculty of Medicine, Faculty of Physical Education and Sport, Second Faculty of Medicine, Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen
- Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis2016 | First Faculty of Medicine, Second Faculty of Medicine
- Biosimilar infliximab in anti-TNF-naïve IBD patients - 1-year clinical follow-up2016 | First Faculty of Medicine
- Severe disease progression of corticosteroid dependent ulcerative colitis in a young child before the era of biological therapy2015 | Second Faculty of Medicine
- Sustainability of biologic treatment in paediatric patients with Crohn's disease: population-based registry analysis2024 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Pilsen
- Tofacitinib in pregnancy: Assessing Pregnancy and Infant Outcomes, Cord Blood and Breast Milk Concentrations2024 | First Faculty of Medicine, Second Faculty of Medicine
- Subcutaneous Infliximab in Refractory Crohn's Disease Patients: A Possible Biobetter?2023 | First Faculty of Medicine, Second Faculty of Medicine, Central Library of Charles University, Third Faculty of Medicine
- Pulmonary tularaemia in a female adolescent with inflammatory bowel disease receiving infliximab: Do not miss the diagnosis2023 | Second Faculty of Medicine, Faculty of Medicine in Pilsen
- Postvaccination Immunogenicity of BNT162b2 SARS-CoV-2 Vaccine and Its Predictors in Pediatric Inflammatory Bowel Disease2023 | Second Faculty of Medicine
Loading network view...